CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 1,521 Shares

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 1,521 shares of CeriBell stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $24.02, for a total transaction of $36,534.42. Following the transaction, the chief financial officer directly owned 146,600 shares in the company, valued at approximately $3,521,332. This represents a 1.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Stock Performance

Shares of CeriBell stock opened at $23.95 on Wednesday. The business’s fifty day simple moving average is $19.77 and its 200 day simple moving average is $19.27. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $25.33. The firm has a market capitalization of $919.20 million, a P/E ratio of -13.61 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. As a group, analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CBLL shares. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Canaccord Genuity Group raised their target price on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. BTIG Research boosted their target price on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Finally, Barclays upgraded CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.40.

Key Stories Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Neutral Sentiment: CEO Xingjuan Chao, CFO Scott Blumberg, CTO Raymond Woo, CRO Joseph S. Manni and VP David Foehr collectively sold approximately 12,781 shares for about $307,000. Each filing stated that the shares were sold to cover tax-withholding obligations after equity awards vested, and the executives retained substantial remaining holdings. SEC insider transaction filings
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from zero shares on August 10, with a zero-day days-to-cover ratio. Because the figures include a “NaN” change and may reflect incomplete or anomalous reporting, they provide little actionable information about bearish positioning.
• Negative Sentiment: The cluster of sales by multiple senior executives could create a modest overhang for CBLL, particularly with the stock trading close to its 12-month peak. However, the relatively small size of the transactions and their stated tax-related purpose lessen the signal that management is broadly reducing exposure.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio bought a new stake in CeriBell during the 1st quarter valued at $27,000. Caitong International Asset Management Co. Ltd grew its position in shares of CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell during the 3rd quarter valued at about $33,000. CWM LLC increased its holdings in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after acquiring an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in shares of CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.